🇺🇸 FDA
Patent

US 8324368

GNAQ targeted dsRNA compositions and methods for inhibiting expression

granted A61KA61K31/713A61P

Quick answer

US patent 8324368 (GNAQ targeted dsRNA compositions and methods for inhibiting expression) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K31/713, A61P, A61P17/00, A61P35/00